Huayuan Wins "Maker in China" Innovation Award! Its Subsidiary Huajin Bio Wins Third Prize

Date： 2025-10-22

On October 21, 2025, the 10th "Maker in China" Shenzhen SME Innovation and Entrepreneurship Competition successfully concluded. Huayuan Regenerative Medicine Co., Ltd., an Efung Capital portfolio company, stood out among numerous participating enterprises with its "Implantable Bioartificial Organ Development" project and won the Innovation Award of the competition.

Its subsidiary, Huajin Bio, won the Third Prize with its "Human Kidney Organoid Modeling and Translational Research Platform Based on Stem Cells" project.

The "Maker in China" SME Innovation and Entrepreneurship Competition is co-hosted by the Ministry of Industry and Information Technology and the Ministry of Finance. It is one of the most authoritative and influential national-level competitions in China's SME sector. These awards not only represent high recognition of the technological strength and market potential of Huayuan Regenerative Medicine and its subsidiary Huajin Bio but also demonstrate the competitiveness of life science enterprises on the innovation track.

Previous：CoreRay’s 3 Key Products Secure EU CE CeNext：Beixin Life and Ying Minda Selected as N

Related News / Recommended news More

Efung Capital CEO Zhu Pai Attends BIOCHINA 2026: Discussing the New Ecosystem of LP-GP Collaboration

2026 - 03 - 24

In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...

Frontier Biotechnologies Enters Exclusive License Agreement with GSK for siRNA Pipeline Products

2026 - 03 - 25

Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio News

2026 - 03 - 06

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...

Viestar’s Confocal Microscopy Products Selected as Outstanding Domestic Medical Equipment

2026 - 03 - 05

The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...